
    
      CC-90002-ST-001 is an open-label, Phase 1, dose escalation, first in human (FIH) clinical
      study of CC-90002, administered by intravenous (IV) infusion, in subjects with advanced,
      refractory solid and hematologic cancers.

      The study will be conducted in two parts. Part A dose escalation phase will explore
      escalating dose cohorts of the study drug CC-90002.

      Part B dose escalation will explore escalating doses of CC-90002 in combination with
      rituximab in subjects with CD20-positive NHL.
    
  